About The Study: This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to ...

Hollie Adams/Reuters In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide ...

Hollie Adams/Reuters In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide, the ...

(Image Credits: Pexel) A new study has revealed that off-label use of semaglutide (Ozempic) and tirzepatide (Mounjaro) leads to significant reductions in HbA1c levels and body weight among adults ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and tirzepatide leads to significant reductions in HbA1c levels and body weight ...

FDA acted within its discretion in declaring end to shortage Compounders must stop making their versions of Zepbound Drug compounders making copycat versions of Eli Lilly & Co. ’s weight loss drug ...

Credit: Eviart via Shutterstock. A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in ...

Zepbound (tirzepatide) can cause side effects that range from mild to serious. More common side effects include nausea, diarrhea, and constipation. If side effects from Zepbound become hard to ...

Drug firm Alembic Pharmaceuticals Ltd on Friday (March 7) announced the completion of a scheduled inspection by the United States Food and Drug Administration (FDA) at its bioequivalence facility in ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Larger outsourcing facilities, which are FDA-regulated and can create prescription-specific compounded drugs as well as bulk orders, must cease compounding, distributing or dispensing tirzepatide ...